![\"\"](\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2021\/09\/Filctem-regionali.png\")
<\/p>\n<\/p>\n
<\/p>\n
Question on Scientific Information of the drug<\/strong><\/span><\/p>\n Very kind director Nicola Magrini<\/span> Given that:<\/span> In recent years we have been witnessing a revolution in the world of scientific information, which risks accelerating due to the pandemic, with the attempt by some companies to interact with the doctor mainly remotely, without having defined the legal, nor contractual outlines; at the same time, in order to better achieve the objective, new figures are entering the system who, in an attempt to bypass the founding rules of the scientific information service, actually replace the activity of the scientific informant.<\/span><\/p>\n In this context, it becomes necessary to clarify who and how should carry out the activity of providing scientific information to the doctor, thus protecting, as you yourself underlined with the note dated 23\/3\/2021, the health of patients,"guaranteeing the freedom of the contents of scientific information, of which the direct relationship between the scientific representative and the doctor constitutes an irrepressible corollary, a relationship that must always take place in full freedom and autonomy<\/span><\/em>\u201d.<\/span><\/p>\n That said, we would like to raise the following questions:<\/span><\/p>\n Dear director Magrini, your answers will be useful for clarifying the roles and duties of the Scientific Representatives, as well as regulating figures who propose themselves, straddling the roles, in the clumsy attempt to escape from rules and controls.<\/span><\/p>\n Awaiting your kind reply, available for any clarifications, best regards<\/span><\/p>\n Editor's note: We have received and published the query, reported above, from a territorial Filctem CGIL to Dr. Nicola Magrini, Director General of AIFA, on the activity of scientific information. The document was also shared and sent by the Filctem CGIL of Milan and Florence.<\/em><\/p>\n We hope that the questions raised will be a reason for reflection by all trade union organizations and will be the subject of a negotiation aware of the role of the ISF for the renewal of the CCNL\u00a0<\/em><\/p>","protected":false},"excerpt":{"rendered":" Quesito su Informazione Scientifica del Farmaco Gentilissimo direttore Nicola Magrini stante l\u2019attuale legislazione, stante il nostro impegno continuo nel rappresentare le difficolta\u0300 affrontate quotidianamente dai lavoratori in oggetto durante l’espletamento di una funzione necessaria al Servizio Sanitario Nazionale, vorremmo porle alcuni quesiti in merito alla professione di Informatore scientifico del farmaco. Premesso che: \u2022 …<\/p>","protected":false},"author":4,"featured_media":35954,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[21,44],"class_list":["post-60090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-informatori-scientifici","tag-sindacati"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/60090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=60090"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/60090\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/35954"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=60090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=60090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=60090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\ngiven the current legislation, given our ongoing commitment to representing the difficulties faced daily by the workers in question during the performance of a function necessary to the National Health Service, we would like to ask you a few questions regarding the profession of drug sales rep.<\/span><\/p>\n
\n\u2022 Article 31 of Law 833\/78 on scientific information states that \u201cThe national health service is responsible for providing scientific information on drugs and for monitoring the scientific information activity of the companies that hold authorizations to place drugs on the market.". He also adds that "The Minister of Health, having heard the National Health Council, having seen the proposals of the regions, taking into account the Community directives and having evaluated the observations and proposals that will arrive from the Higher Institute of Health and from university and research institutes, as well as from pharmaceutical industry, prepares a multi-year program for scientific information on drugs, also aimed at health education initiatives and lays down rules for the regulation of the aforementioned service and the activity of scientific representatives.<\/span><\/em>\u201d<\/span><\/p>\n\n
\n
\n
![\"\"](\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2021\/09\/Filctem-Lazio-firme.png\")
<\/p>\n
\n